← SynDRA
BELZUTIFAN
SynDRA canonical compound SYN0039936 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | EPAS1 |
|---|
| Mechanism of action | hif modulator |
|---|
| Indication | renal cell carcinoma (rcc) |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- EPAS1 INHIBITOR
- Endothelial PAS domain-containing protein 1 inhibitor
- hif modulator
Drug classes
- Antineoplastic Agents
- Cytochrome P450 3A4 Inducers
- Hypoxia-inducible Factor 2 alpha Inhibitors
- Hypoxia-inducible Factor Inhibitor
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- welireg
- MK-6482
- PT2977
- PT-2977
- MK6482
- Welireg
- 7K28NB895L
- Pt 2977
- MK 6482
- RefChem:58380
- HIF-2alpha Inhibitor PT2977
- DTXCID501763931
- Belzutifan [INN]
- Belzutifan [USAN]
- Welireg (TN)
- Belzutifan [USAN:INN]
- BELZUTIFAN [WHO-DD]
- Belzutifan (JAN/USAN/INN)
- UNII-7K28NB895L
- orb1307837
- BELZUTIFAN [ORANGE BOOK]
- SCHEMBL16560918
- SCHEMBL29388851
- SCHEMBL29458304
- SCHEMBL29828027
- GTPL11251
- PT 2977 [WHO-DD]
- BDBM373040
- GLXC-21323
- EX-A4441
- US9896418, Compound 289
- XRC66824
- MFCD32197212
- NSC825217
- WHO 11196
- AKOS040742518
- AT14994
- compound 2 [PMID: 31282155]
Reported adverse events
- Dizziness
- Fatigue
- Hypoxia
- Nausea
- Weight increased
- Abdominal pain
- Arrhythmia
- Arthralgia
- Constipation
- Cough
- Headache
- Hypertension
Look up BELZUTIFAN in the interactive SynDRA portal →